Find a Clinical Trial

Showing 171 - 180 of 180 Trials

  • Electronic health record-based implementation strategies and decision support for hereditary breast and ovarian cancer genetic testing among multiethnic women (ELISABETH)

    Principal Investigator:

    Katherine D Crew, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this research study is to test how well a new approach—using tools built into the electronic health record (EHR)—can help increase genetic testing for hereditary breast and ovarian cancer (HBOC) in women who have a family history that puts them at higher risk. The study will also look at what helps or gets in the way of using these tools in everyday clinical care. As part of this study, we are also evaluating a website called RealRisks, which is designed to support patients in understanding their risk and making informed decisions about genetic testing. By studying...

  • Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma

    Principal Investigator:

    Lisa Ann Kachnic, MD, FASTRO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05838391

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to find out if performing adaptive planning during the treatment anal cancer will decrease the dose of radiation to normal organs and decrease the side effects. In this study, subjects will have a daily adjustment (adaptation) of their radiation plan as the tumor changes during the radiation treatment. The radiation will be given as part the standard of care treatment with chemotherapy, known as chemo-RT (CRT). Are you Eligible? (Inclusion Criteria) To be considered for this study, you must: 1. Have invasive anal cancer confirmed with biopsy 2. Be greater than 18...

  • IMPACT Trial: Intervention to iMProve AdherenCe equitably

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05496829

    Population:

    Adult

    Phase:

    NA
    Many patients with breast cancer, who also take medicine to prevent heart disease such as a blood pressure medicine or a cholesterol medicine, experience frustration with the large number and difficult scheduling of their medications, known as “pill burden”. This study will help us find out how much “pill burden” exists in subjects with cancer at various stages, and how this intervention can help. Results of this study may help us figure out the best way to help patients manage their medications in the future. Are you Eligible? (Inclusion Criteria) Are you diagnosed...

  • Improving Medications Adherence Equitably among Patients with Metastatic Breast Cancerand Cardiovascular Disease

    Principal Investigator:

    Claire Sathe, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06121453

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to evaluate the effect of a multi-part intervention to reduce barriers to medication use. All subjects who are enrolled in the study will undergo the following interventions: 1) A complete medication reconciliation will be done where you will be asked about all current medication you have been prescribed. This is to create an accurate list of current medications you are taking. 2) A two-time visit with a pharmacist to review all the medicines you take, reasons for not taking medicines, and to create a personalized plan to help you take your medicines. After 4...

  • Post-marketing surveillance of StrataCTX® flexible wound dressing for use as a steroid sparing agent

    Principal Investigator:

    Larisa J Geskin, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04087629

    Population:

    Adult

    Phase:

    NA
    To assess the use of StrataCTX® as a steroid sparing agent for disorders usually treated with topical steroids. Are you Eligible? (Inclusion Criteria) Age ≥ 18 years Ability to sign informed consent document Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel Patients with a diagnosis of CTCL who have intractable pruritus Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief Patients on chemo/immunotherapy with drug induced rash Patients with cutaneous acute graft versus host disease

  • Pilot Study to Assess Feasibility, Acceptability, and Efficacy of a Food Navigation and Food DeliveryIntervention to Reduce Food Insecurity Among Patients with Metastatic Breast Cancer

    Principal Investigator:

    Claire Sathe, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this research study to find out how we can best help patients with metastatic (advanced) breast cancer who sometimes worry not having enough food and provide resources to access the food that they need. We want to test an intervention by taking surveys to determine how it affects the patients, their food environment, and their mental health. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have access to smartphone, tablet, or any type of telephone to complete surveys - Must be able to speak English or Spanish

  • RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

    Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03723928

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care. Are you Eligible? (Inclusion Criteria) Do you have hormone positive, HER-2 negative, metastatic breast cancer? Are you 18 years of age or older? Are you willing to be monitored for your disease for the duration of this study?

  • Sequencing-guided cHemotherapy Optimization using Real-Time Evaluation in Newly Diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA

    Principal Investigator:

    Hua-Jay J Cherng, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1) determine whether it is feasible to measure ctDNA in real-time during standard treatment for newly diagnosed DLBCL, and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of...

  • Whole-Food Plant-Based Diet (WFPBD) to Control Weight and Metabo-Inflammation in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT): A Multi-Center Randomized Control Trial

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05471414

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to assess the efficacy of a home-delivered whole-food plant- based diet (WFPBD) intervention in promoting weight loss in overweight or obese men with prostate cancer receiving androgen deprivation therapy (ADT), as compared to general nutritional counseling only. Another purpose is to assess how easy or difficult it is for patients to comply with a whole-foods plant-based diet, first when it is delivered to their home and later when they have to prepare it on their own. This trial will test whether an intervention such as a special diet is feasible, i.e., whether...

  • Young, Empowered Strong (YES): A web-based patient-reported symptom monitoring andself-management portal for adolescent and young adult breast cancer survivors

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04906200

    Population:

    Pediatrics/Adult

    Phase:

    NA
    The Young, Empowered & Strong (YES) study is opened to women who were diagnosed with breast cancer between the ages of 15 and 39 years. Women will need to be within 3 years of the end of early active treatment (e.g. surgery, chemotherapy not including HER2-directed therapy, radiation), and have no know evidence of breast cancer recurrence. The study team designed a web portal, called YES (Young, Empowered & Strong), with information for breast cancer survivors. A web portal is similar to a website where people go for a specific kind of information. We want to find out if using the YES...

Pages